241 related articles for article (PubMed ID: 30470838)
1. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation.
Czech J; Cordua S; Weinbergerova B; Baumeister J; Crepcia A; Han L; Maié T; Costa IG; Denecke B; Maurer A; Schubert C; Feldberg K; Gezer D; Brümmendorf TH; Müller-Newen G; Mayer J; Racil Z; Kubesova B; Knudsen T; Sørensen AL; Holmström M; Kjær L; Skov V; Larsen TS; Hasselbalch HC; Chatain N; Koschmieder S
Leukemia; 2019 Apr; 33(4):995-1010. PubMed ID: 30470838
[TBL] [Abstract][Full Text] [Related]
2. Differential roles of STAT1 and STAT2 in the sensitivity of JAK2V617F- vs. BCR-ABL-positive cells to interferon alpha.
Schubert C; Allhoff M; Tillmann S; Maié T; Costa IG; Lipka DB; Schemionek M; Feldberg K; Baumeister J; Brümmendorf TH; Chatain N; Koschmieder S
J Hematol Oncol; 2019 Apr; 12(1):36. PubMed ID: 30940163
[TBL] [Abstract][Full Text] [Related]
3. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CD34+ hematopoietic progenitor cells in JAK2V617F and CALR-mutated myeloproliferative neoplasms.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Camacho L; Fernández-Rodríguez MC; Pairet S; Besses C
Leuk Res; 2016 Sep; 48():11-5. PubMed ID: 27427771
[TBL] [Abstract][Full Text] [Related]
5. Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms.
Guo H; Chen X; Tian R; Chang J; Li J; Tan Y; Xu Z; Ren F; Zhao J; Pan J; Zhang N; Wang X; He J; Yang W; Wang H
PLoS One; 2015; 10(9):e0138250. PubMed ID: 26375990
[TBL] [Abstract][Full Text] [Related]
6. CALR, JAK2 and MPL mutation status in Argentinean patients with BCR-ABL1- negative myeloproliferative neoplasms.
Ojeda MJ; Bragós IM; Calvo KL; Williams GM; Carbonell MM; Pratti AF
Hematology; 2018 May; 23(4):208-211. PubMed ID: 28990497
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in JAK2V617F-positive myeloproliferative neoplasms.
Baumeister J; Chatain N; Hubrich A; Maié T; Costa IG; Denecke B; Han L; Küstermann C; Sontag S; Seré K; Strathmann K; Zenke M; Schuppert A; Brümmendorf TH; Kranc KR; Koschmieder S; Gezer D
Leukemia; 2020 Apr; 34(4):1062-1074. PubMed ID: 31728053
[TBL] [Abstract][Full Text] [Related]
8. The effects of mutational profiles on phenotypic presentation of myeloproliferative neoplasm subtypes in Bosnia: 18 year follow-up.
Kurtovic-Kozaric A; Islamagic E; Komic H; Bilalovic N; Eminovic I; Burekovic A; Uzunovic A; Kurtovic S
Bosn J Basic Med Sci; 2020 May; 20(2):236-247. PubMed ID: 31668145
[TBL] [Abstract][Full Text] [Related]
9. IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in JAK2V617F-positive myeloproliferative neoplasms.
de Melo Campos P; Machado-Neto JA; Eide CA; Savage SL; Scopim-Ribeiro R; da Silva Souza Duarte A; Favaro P; Lorand-Metze I; Costa FF; Tognon CE; Druker BJ; Olalla Saad ST; Traina F
Oncotarget; 2016 Feb; 7(6):6948-59. PubMed ID: 26755644
[TBL] [Abstract][Full Text] [Related]
10. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
11. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Mosca M; Hermange G; Tisserand A; Noble R; Marzac C; Marty C; Le Sueur C; Campario H; Vertenoeil G; El-Khoury M; Catelain C; Rameau P; Gella C; Lenglet J; Casadevall N; Favier R; Solary E; Cassinat B; Kiladjian JJ; Constantinescu SN; Pasquier F; Hochberg ME; Raslova H; Villeval JL; Girodon F; Vainchenker W; Cournède PH; Plo I
Blood; 2021 Dec; 138(22):2231-2243. PubMed ID: 34407546
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants.
Chachoua I; Pecquet C; El-Khoury M; Nivarthi H; Albu RI; Marty C; Gryshkova V; Defour JP; Vertenoeil G; Ngo A; Koay A; Raslova H; Courtoy PJ; Choong ML; Plo I; Vainchenker W; Kralovics R; Constantinescu SN
Blood; 2016 Mar; 127(10):1325-35. PubMed ID: 26668133
[TBL] [Abstract][Full Text] [Related]
13. JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients.
Shires KL; Rust AJ; Harryparsad R; Coburn JA; Gopie RE
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):291-302. PubMed ID: 37023224
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological differences exist between CALR- and JAK2-mutated myeloproliferative neoplasms despite a similar molecular landscape: data from targeted next-generation sequencing in the diagnostic laboratory.
Agarwal R; Blombery P; McBean M; Jones K; Fellowes A; Doig K; Forsyth C; Westerman DA
Ann Hematol; 2017 May; 96(5):725-732. PubMed ID: 28161773
[TBL] [Abstract][Full Text] [Related]
15. Calreticulin Mutations in Bulgarian MPN Patients.
Pavlov I; Hadjiev E; Alaikov T; Spassova S; Stoimenov A; Naumova E; Shivarov V; Ivanova M
Pathol Oncol Res; 2018 Jan; 24(1):171-174. PubMed ID: 28411309
[TBL] [Abstract][Full Text] [Related]
16. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia.
Lim KH; Chen CG; Chang YC; Chiang YH; Kao CW; Wang WT; Chang CY; Huang L; Lin CS; Cheng CC; Cheng HI; Su NW; Lin J; Chang YF; Chang MC; Hsieh RK; Lin HC; Kuo YY
Oncotarget; 2017 May; 8(20):32476-32491. PubMed ID: 28415571
[TBL] [Abstract][Full Text] [Related]
17. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
18. No increase of JAK2 46/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation.
Gau JP; Chen CC; Chou YS; Liu CJ; Yu YB; Hsiao LT; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH
Blood Cells Mol Dis; 2015 Jun; 55(1):36-9. PubMed ID: 25976465
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Matsumoto N; Mori S; Hasegawa H; Sasaki D; Mori H; Tsuruda K; Imanishi D; Imaizumi Y; Hata T; Kaku N; Kosai K; Uno N; Miyazaki Y; Yanagihara K
Clin Chim Acta; 2016 Nov; 462():166-173. PubMed ID: 27693531
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms.
Grinsztejn E; Percy MJ; McClenaghan D; Quintana M; Cuthbert RJ; McMullin MF
Int J Lab Hematol; 2016 Feb; 38(1):102-6. PubMed ID: 26555437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
